US20090145087A1 - Cold storage of organotypically cultured skin equivalents for clinical applications - Google Patents

Cold storage of organotypically cultured skin equivalents for clinical applications Download PDF

Info

Publication number
US20090145087A1
US20090145087A1 US12/271,455 US27145508A US2009145087A1 US 20090145087 A1 US20090145087 A1 US 20090145087A1 US 27145508 A US27145508 A US 27145508A US 2009145087 A1 US2009145087 A1 US 2009145087A1
Authority
US
United States
Prior art keywords
edge
tissue
gel support
skin equivalent
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/271,455
Other languages
English (en)
Inventor
B. Lynn Allen-Hoffmann
John C. Pirnstill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stratatech Corp
Original Assignee
Stratatech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stratatech Corp filed Critical Stratatech Corp
Priority to US12/271,455 priority Critical patent/US20090145087A1/en
Assigned to STRATATECH CORPORATION reassignment STRATATECH CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ALLEN-HOFFMANN, B. LYNN, PIRNSTILL, JOHN C.
Publication of US20090145087A1 publication Critical patent/US20090145087A1/en
Assigned to DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT reassignment DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Assignors: STRATATECH CORPORATION
Priority to US15/375,755 priority patent/US10743533B2/en
Assigned to MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.), MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.), INO THERAPEUTICS LLC, SpecGx LLC, MALLINCKRODT VETERINARY, INC., ST SHARED SERVICES LLC, STRATATECH CORPORATION, MALLINCKRODT ENTERPRISES LLC, MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED, MALLINCKRODT CB LLC, MALLINCKRODT US POOL LLC, LAFAYETTE PHARMACEUTICALS LLC, MEH, INC., LUDLOW LLC (F/K/A LUDLOW CORPORATION), MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED), IKARIA THERAPEUTICS LLC, IMC EXPLORATION COMPANY, SUCAMPO PHARMA AMERICAS LLC, MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.), LIEBEL-FLARSHEIM COMPANY LLC, OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.), MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.), MALLINCKRODT LLC, MNK 2011 LLC (F/K/A MALLINCKRODT INC.), MALLINCKRODT US HOLDINGS LLC, MALLINCKRODT CARRIBEAN, INC., VTESSE LLC (F/K/A VTESSE INC.), THERAKOS, INC., CNS THERAPEUTICS, INC., MALLINCKRODT INTERNATIONAL FINANCE S.A., MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED), MALLINCKRODT FINANCE GMBH, INFACARE PHARMACEUTICAL CORPORATION reassignment MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.) RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 040059, FRAME 0222 Assignors: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/0231—Chemically defined matrices, e.g. alginate gels, for immobilising, holding or storing cells, tissue or organs for preservation purposes; Chemically altering or fixing cells, tissue or organs, e.g. by cross-linking, for preservation purposes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0236—Mechanical aspects
    • A01N1/0263—Non-refrigerated containers specially adapted for transporting or storing living parts whilst preserving, e.g. cool boxes, blood bags or "straws" for cryopreservation
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0236—Mechanical aspects
    • A01N1/0263—Non-refrigerated containers specially adapted for transporting or storing living parts whilst preserving, e.g. cool boxes, blood bags or "straws" for cryopreservation
    • A01N1/0273—Transport containers

Definitions

  • the present invention relates generally to systems and methods for shipping and storing skin equivalents made by organotypic culture that are to be used for skin grafting to human patients.
  • APLIGRAF requires about four weeks to manufacture, is usable for less than ten days and must be maintained between 20 and 23° C. until used.
  • EPICEL is transported by a nurse from Cambridge, Mass. to the point-of-use in a portable incubator and is used immediately upon arrival. Such constraints represent significant challenges to developing convenient and cost-effective products.
  • the present invention provides methods of shipping an organotypically cultured skin equivalent to a user and using the skin equivalent in a skin grafting procedure on a human patient comprising: providing the organotypically cultured skin equivalent comprising dermal and epidermal layers and a sterile package comprising a gel support; packaging the skin equivalent in a sterile package under sterile conditions so that the skin equivalent contacts the gel support; lowering the temperature of the sterile package to 2-8 degrees Celsius; shipping the sterile package to a user at 2-8 degrees Celsius; storing the sterile package at the site of use at 2-8 degrees Celsius wherein the sterility and integrity of the sterile package are maintained; and removing the organotypically cultured skin equivalent from the package and applying to a patient without an intervening culture step.
  • the present invention is not limited to skin equivalents comprising any particular types of keratinocytes.
  • the organotypically cultured skin equivalent comprises NIKS cells.
  • the present invention is not limited to any particular type of gel support.
  • the gel support is an agarose gel support.
  • the present invention is not limited to any particular type of sterile package.
  • the sterile package is heat sealable.
  • the skin equivalent contacts the gel support via a permeable membrane.
  • the present invention provides methods of shipping and storing an organotypically cultured skin equivalent for use in a skin grafting procedure comprising: providing the organotypically cultured skin equivalent comprising dermal and epidermal layers and a sterile package comprising a gel support; packaging the skin equivalent in a sterile package under sterile conditions so that the skin equivalent contacts the gel support on a packaging date; lowering the temperature of the sterile package to 2-8 degrees Celsius; shipping the sterile package to a user at 2-8 degrees Celsius; storing the sterile package at the site of use at 2-8 degrees Celsius wherein the sterility and integrity of the sterile package are maintained for from 8 to 15 days from the packaging date.
  • the present invention is not limited to skin equivalents comprising any particular types of keratinocytes.
  • the organotypically cultured skin equivalent comprises NIKS cells.
  • the present invention is not limited to any particular type of gel support.
  • the gel support is an agarose gel support.
  • the present invention is not limited to any particular type of sterile package.
  • the sterile package is heat sealable.
  • the skin equivalent contacts the gel support via a permeable membrane.
  • the present invention provides methods of shipping an organotypically cultured skin equivalent to a user for use in a skin grafting procedure comprising: providing the organotypically cultured skin equivalent comprising dermal and epidermal layers and a sterile package comprising a gel support, wherein the gel support is formed with a minimal media; packaging the skin equivalent in a sterile package under sterile conditions so that the skin equivalent contacts the gel support; lowering the temperature of the sterile package to 2-8 degrees Celsius; shipping the sterile package to a user at 2-8 degrees Celsius; storing the sterile package at the site of use 2-8 degrees Celsius wherein the sterility and integrity of the sterile package are maintained.
  • the present invention is not limited to skin equivalents comprising any particular types of keratinocytes.
  • the organotypically cultured skin equivalent comprises NIKS cells.
  • the present invention is not limited to any particular type of gel support.
  • the gel support is an agarose gel support.
  • the present invention is not limited to any particular type of sterile package.
  • the sterile package is heat sealable.
  • the skin equivalent contacts the gel support via a permeable membrane.
  • kits comprising: a shipping chamber comprising a gel support comprising a minimal media; a skin equivalent supported on a permeable membrane in contact with the gel support; wherein the shipping chamber is contained with a sterile pouch.
  • the present invention is not limited to skin equivalents comprising any particular types of keratinocytes.
  • the organotypically cultured skin equivalent comprises NIKS cells.
  • the present invention is not limited to any particular type of gel support.
  • the gel support is an agarose gel support.
  • the present invention is not limited to any particular type of sterile package.
  • the sterile package is heat sealable.
  • the skin equivalent contacts the gel support via a permeable membrane.
  • the present invention further provides articles of manufacture comprising a shipping chamber comprising a chamber top and a chamber bottom having a surface having thereon a gel support, said article further comprising a skin equivalent on a permeable membrane, said permeable membrane in contact with said gel support, said article further comprising extensions extending from said chamber top so that when said chamber top is placed on said chamber bottom said skin equivalent is secured against said gel support.
  • the gel support is formed with minimal media.
  • FIG. 1 depicts a shipping chamber of the present invention.
  • FIG. 2 is a viability data graft.
  • FIG. 3 is a viability data graft.
  • FIG. 4 is a viability data graft.
  • FIG. 5 is a viability data graft.
  • FIG. 6 is a viability data graft.
  • FIG. 7 is a table presenting viability data.
  • FIG. 8 is a table presenting barrier function summary data.
  • human skin equivalent and “human skin substitute” are used interchangeably to refer to an in vitro derived culture of keratinocytes that has stratified into squamous epithelia.
  • the skin equivalents are produced by organotypic culture and include a dermal layer in addition to a keratinocyte layer.
  • NIKS® cells refers to cells having the characteristics of the cells deposited as cell line ATCC CRL-1219.
  • the term “homology” refers to a degree of complementarity. There may be partial homology or complete homology (i.e., identity).
  • a partially complementary sequence is one that at least partially inhibits a completely complementary sequence from hybridizing to a target nucleic acid and is referred to using the functional term “substantially homologous.”
  • the term “inhibition of binding,” when used in reference to nucleic acid binding, refers to inhibition of binding caused by competition of homologous sequences for binding to a target sequence.
  • the inhibition of hybridization of the completely complementary sequence to the target sequence may be examined using a hybridization assay (Southern or Northern blot, solution hybridization and the like) under conditions of low stringency.
  • a substantially homologous sequence or probe will compete for and inhibit the binding (i.e., the hybridization) of a completely homologous to a target under conditions of low stringency. This is not to say that conditions of low stringency are such that non-specific binding is permitted; low stringency conditions require that the binding of two sequences to one another be a specific (i.e., selective) interaction.
  • the absence of non-specific binding may be tested by the use of a second target that lacks even a partial degree of complementarity (e.g., less than about 30% identity); in the absence of non-specific binding the probe will not hybridize to the second non-complementary target.
  • the term “gene” refers to a nucleic acid (e.g., DNA) sequence that comprises coding sequences necessary for the production of a polypeptide or precursor (e.g., KGF-2).
  • the polypeptide can be encoded by a full length coding sequence or by any portion of the coding sequence so long as the desired activity or functional properties (e.g., enzymatic activity, ligand binding, signal transduction, etc.) of the full-length or fragment are retained.
  • the term also encompasses the coding region of a structural gene and the including sequences located adjacent to the coding region on both the 5′ and 3′ ends for a distance of about 1 kb on either end such that the gene corresponds to the length of the full-length mRNA.
  • sequences that are located 5′ of the coding region and which are present on the mRNA are referred to as 5′ untranslated sequences.
  • sequences that are located 3′ or downstream of the coding region and that are present on the mRNA are referred to as 3′ untranslated sequences.
  • the term “gene” encompasses both cDNA and genomic forms of a gene.
  • a genomic form or clone of a gene contains the coding region interrupted with non-coding sequences termed “introns” or “intervening regions” or “intervening sequences.” Introns are segments of a gene that are transcribed into nuclear RNA (hnRNA); introns may contain regulatory elements such as enhancers.
  • Introns are removed or “spliced out” from the nuclear or primary transcript; introns therefore are absent in the messenger RNA (mRNA) transcript.
  • mRNA messenger RNA
  • the mRNA functions during translation to specify the sequence or order of amino acids in a nascent polypeptide.
  • nucleic acid molecule encoding As used herein, the terms “nucleic acid molecule encoding,” “DNA sequence encoding,” and “DNA encoding” refer to the order or sequence of deoxyribonucleotides along a strand of deoxyribonucleic acid. The order of these deoxyribonucleotides determines the order of amino acids along the polypeptide (protein) chain. The DNA sequence thus codes for the amino acid sequence.
  • the term “recombinant DNA molecule” as used herein refers to a DNA molecule that is comprised of segments of DNA joined together by means of molecular biological techniques.
  • purified or “to purify” refers to the removal of contaminants from a sample.
  • vector is used in reference to nucleic acid molecules that transfer DNA segment(s) from one cell to another.
  • vehicle is sometimes used interchangeably with “vector.”
  • expression vector refers to a recombinant DNA molecule containing a desired coding sequence and appropriate nucleic acid sequences necessary for the expression of the operably linked coding sequence in a particular host organism.
  • Nucleic acid sequences necessary for expression in prokaryotes usually include a promoter, an operator (optional), and a ribosome binding site, often along with other sequences.
  • Eukaryotic cells are known to utilize promoters, enhancers, and termination and polyadenylation signals.
  • “Operably linked” refers to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner.
  • a regulatory sequence is “operably linked” to a coding sequence when it is joined in such a way that expression of the coding sequence is achieved under conditions compatible with the regulatory sequence.
  • transfection refers to the introduction of foreign DNA into eukaryotic cells. Transfection may be accomplished by a variety of means known to the art including calcium phosphate-DNA co-precipitation, DEAE-dextran-mediated transfection, polybrene-mediated transfection, electroporation, microinjection, liposome fusion, lipofection, protoplast fusion, retroviral infection, and biolistics.
  • stable transfection or “stably transfected” refers to the introduction and integration of foreign DNA into the genome of the transfected cell.
  • stable transfectant refers to a cell that has stably integrated foreign DNA into the genomic DNA.
  • transient transfection or “transiently transfected” refers to the introduction of foreign DNA into a cell where the foreign DNA fails to integrate into the genome of the transfected cell.
  • the foreign DNA persists in the nucleus of the transfected cell for several days. During this time the foreign DNA is subject to the regulatory controls that govern the expression of endogenous genes in the chromosomes.
  • transient transfectant refers to cells that have taken up foreign DNA but have failed to integrate this DNA.
  • the present invention relates generally to systems and methods for shipping and storing skin equivalents made by organotypic culture that are to be used for skin grafting to human patients.
  • the present invention relates to methods for production and packaging of a sterile skin equivalent using aseptic techniques and maintaining the sterility of the skin equivalent during storage for up to 15 days until opened in a sterile surgical field for clinical use.
  • the present invention is not limited to the use of any particular source of cells that are capable of differentiating into squamous epithelia. Indeed, the present invention contemplates the use of a variety of cell lines and sources that can differentiate into squamous epithelia, including both primary and immortalized keratinocytes. Sources of cells include keratinocytes and dermal fibroblasts biopsied from humans and cavaderic donors (Auger et al, In Vitro Cell. Dev. Biol.—Animal 36:96-103; U.S. Pat. Nos. 5,968,546 and 5,693,332, each of which is incorporated herein by reference), neonatal foreskins (Asbill et al, Pharm.
  • NIKS® cells are utilized.
  • the discovery of a novel human keratinocyte cell line provides an opportunity to genetically engineer human keratinocytes.
  • a unique advantage of the NIKS® cells is that they are a consistent source of genetically-uniform, pathogen-free human keratinocytes. For this reason, they are useful for the application of genetic engineering and genomic gene expression approaches to provide skin equivalent cultures with properties more similar to human skin.
  • NIKS® keratinocyte cell line identified and characterized at the University of Wisconsin, is nontumorigenic, exhibits a stable karyotype, and exhibits normal differentiation both in monolayer and organotypic culture.
  • NIKS® cells form fully stratified skin equivalents in culture. These cultures are indistinguishable by all criteria tested thus far from organotypic cultures formed from primary human keratinocytes.
  • the immortalized NIKS® cells will continue to proliferate in monolayer culture indefinitely. This provides an opportunity to genetically manipulate the cells and isolate new clones of cells with new useful properties (Allen-Hoffmann et al., J. Invest. Dermatol., 114(3): 444-455 (2000)).
  • the NIKS® cells arose from the BC-1-Ep strain of human neonatal foreskin keratinocytes isolated from an apparently normal male infant. In early passages, the BC-1-Ep cells exhibited no morphological or growth characteristics that were atypical for cultured normal human keratinocytes. Cultivated BC-1-Ep cells exhibited stratification as well as features of programmed cell death. To determine replicative lifespan, the BC-1-Ep cells were serially cultivated to senescence in standard keratinocyte growth medium at a density of 3 ⁇ 10 5 cells per 100-mm dish and passaged at weekly intervals (approximately a 1:25 split).
  • the keratinocytes that emerged from the original senescencing population were originally designated BC-1-Ep/Spontaneous Line and are now termed NIKS®.
  • the NIKS® cell line has been screened for the presence of proviral DNA sequences for HIV-1, HIV-2, EBV, CMV, HTLV-1, HTLV-2, HBV, HCV, B-19 parvovirus, HPV-16 and HPV-31 using either PCR or Southern analysis. None of these viruses were detected.
  • Chromosomal analysis was performed on the parental BC-1-Ep cells at passage 3 and NIKS cells at passages 31 and 54.
  • the parental BC-1-Ep cells have a normal chromosomal complement of 46, XY.
  • all NIKS® cells contained 47 chromosomes with an extra isochromosome of the long arm of chromosome 8. No other gross chromosomal abnormalities or marker chromosomes were detected.
  • all cells contained the isochromosome 8.
  • the DNA fingerprints for the NIKS® cell line and the BC-1-Ep keratinocytes are identical at all twelve loci analyzed demonstrating that the NIKS® cells arose from the parental BC-1-Ep population.
  • the odds of the NIKS® cell line having the parental BC-1-Ep DNA fingerprint by random chance is 4 ⁇ 10 ⁇ 16 .
  • the DNA fingerprints from three different sources of human keratinocytes, ED-1-Ep, SCC4 and SCC13y are different from the BC-1-Ep pattern. This data also shows that keratinocytes isolated from other humans, ED-1-Ep, SCC4, and SCC13y, are unrelated to the BC-1-Ep cells or each other.
  • the NIKS® DNA fingerprint data provides an unequivocal way to identify the NIKS® cell line.
  • Loss of p53 function is associated with an enhanced proliferative potential and increased frequency of immortality in cultured cells.
  • the sequence of p53 in the NIKS® cells is identical to published p53 sequences (GenBank accession number: M14695). In humans, p53 exists in two predominant polymorphic forms distinguished by the amino acid at codon 72. Both alleles of p53 in the NIKS® cells are wild-type and have the sequence CGC at codon 72, which codes for an arginine. The other common form of p53 has a proline at this position. The entire sequence of p53 in the NIKS® cells is identical to the BC-1-Ep progenitor cells. Rb was also found to be wild-type in NIKS® cells.
  • Anchorage-independent growth is highly correlated to tumorigenicity in vivo. For this reason, the anchorage-independent growth characteristics of NIKS® cells in agar or methylcellulose-containing medium was investigated. After 4 weeks in either agar- or methylcellulose-containing medium, NIKS® cells remained as single cells. The assays were continued for a total of 8 weeks to detect slow growing variants of the NIKS® cells. None were observed.
  • the organotypically cultured skin equivalents of the present invention comprise a dermal equivalent formed from collagen or a similar material and fibroblasts.
  • the keratinocytes for example NIKS® cells or a combination of NIKS® cells and cell from a patient are seeded onto the dermal equivalent and form an epidermal layer characterized by squamous differentiation following the organotypic culture process.
  • cornified envelopes For cells in surface culture, a marker of squamous differentiation, the formation cornified envelopes was monitored. In cultured human keratinocytes, early stages of cornified envelope assembly result in the formation of an immature structure composed of involucrin, cystatin- ⁇ and other proteins, which represent the innermost third of the mature cornified envelope. Less than 2% of the keratinocytes from the adherent BC-1-Ep cells or the NIKS® cell line produce cornified envelopes. This finding is consistent with previous studies demonstrating that actively growing, subconfluent keratinocytes produce less than 5% cornified envelopes.
  • the cells were removed from surface culture and suspended for 24 hours in medium made semi-solid with methylcellulose.
  • Many aspects of terminal differentiation, including differential expression of keratins and cornified envelope formation can be triggered in vitro by loss of keratinocyte cell-cell and cell-substratum adhesion.
  • the NIKS® keratinocytes produced as many as and usually more cornified envelopes than the parental keratinocytes.
  • NIKS® keratinocytes can undergo squamous differentiation
  • the cells were cultivated in organotypic culture. Keratinocyte cultures grown on plastic substrata and submerged in medium replicate but exhibit limited differentiation. Specifically, human keratinocytes become confluent and undergo limited stratification producing a sheet consisting of 3 or more layers of keratinocytes. By light and electron microscopy there are striking differences between the architecture of the multilayered sheets formed in tissue culture and intact human skin. In contrast, organotypic culturing techniques allow for keratinocyte growth and differentiation under in vivo-like conditions. Specifically, the cells adhere to a physiological substratum consisting of dermal fibroblasts embedded within a fibrillar collagen base.
  • the organotypic culture is maintained at the air-medium interface. In this way, cells in the upper sheets are air-exposed while the proliferating basal cells remain closest to the gradient of nutrients provided by diffusion through the collagen gel. Under these conditions, correct tissue architecture is formed.
  • Several characteristics of a normal differentiating epidermis are evident. In both the parental cells and the NIKS® cell line a single layer of cuboidal basal cells rests at the junction of the epidermis and the dermal equivalent. The rounded morphology and high nuclear to cytoplasmic ratio is indicative of an actively dividing population of keratinocytes. In normal human epidermis, as the basal cells divide they give rise to daughter cells that migrate upwards into the differentiating layers of the tissue.
  • the daughter cells increase in size and become flattened and squamous. Eventually these cells enucleate and form cornified, keratinized structures. This normal differentiation process is evident in the upper layers of both the parental cells and the NIKS® cells. The appearance of flattened squamous cells is evident in the upper layers of keratinocytes and demonstrates that stratification has occurred in the organotypic cultures. In the uppermost part of the organotypic cultures the enucleated squames peel off the top of the culture. To date, no histological differences in differentiation at the light microscope level between the parental keratinocytes and the NIKS® keratinocyte cell line grown in organotypic culture have been observed
  • Hemidesmosomes are specialized structures that increase adhesion of the keratinocytes to the basal lamina and help maintain the integrity and strength of the tissue. The presence of these structures was especially evident in areas where the parental cells or the NIKS® cells had attached directly to the porous support. These findings are consistent with earlier ultrastructural findings using human foreskin keratinocytes cultured on a fibroblast-containing porous support. Analysis at both the light and electron microscopic levels demonstrate that the NIKS® cell line in organotypic culture can stratify, differentiate, and form structures such as desmosomes, basal lamina, and hemidesmosomes found in normal human epidermis.
  • the present invention provides method, kits and devices for shipping and storing an organotypically cultured skin equivalent to a user for use in a skin grafting procedure.
  • the present invention is not limited to any particular method of producing organotypically cultured human skin equivalents. Indeed, a variety of methods may be used.
  • the organotypically cultured skin equivalents of the present invention are produced by the methods described above and in the examples, or modifications thereof.
  • the organotypically cultured skin equivalents are aseptically packaged at the site of manufacture for shipment to a site of use. The date this occurs on is the “packaging date.”
  • the organotypically cultured skin equivalents are sealed in a sterile package under sterile conditions.
  • the organotypically cultured skin equivalents are placed in contact with a gel support.
  • the present invention is not limited to any particular gel support.
  • the gel support is agarose.
  • the gel support is produced with or comprises a minimal media.
  • organotypically cultured skin equivalents can be supported for extended periods of time on gel supports supplemented with minimal media as opposed to complex media comprising active biological agents such as growth factors (e.g., epidermal growth factor, insulin and insulin-like growth factor 1) and steroids (e.g., hydrocortisone).
  • active biological agents such as growth factors (e.g., epidermal growth factor, insulin and insulin-like growth factor 1) and steroids (e.g., hydrocortisone).
  • Minimal media are media that are substantially free of biologically active growth factors and hormones.
  • the media comprises less than about 1 mg/ml, 0.5 mg/ml, 100 ug/ml, 50 ug/ml, 10 ug/ml, 1 ug/ml, 500 ng/ml, 100 ng/ml, 10 ng/ml, 1 ng/ml or 0.1 ng/ml of a growth factor (e.g., EGF, IGF-1, or insulin) or steroid (e.g., hydrocortisone).
  • a growth factor e.g., EGF, IGF-1, or insulin
  • steroid e.g., hydrocortisone
  • the minimal media is a mixture of DMEM and F12 and is serum free.
  • the gel support is formed or placed in a shipping chamber.
  • a shipping chamber of the present invention is illustrated in FIG. 1 .
  • the shipping chamber 100 is preferably constructed from a p150 tissue culture dish with a diameter of approximately 150 mm and height of approximately 20 mm.
  • the shipping chamber preferably comprises a chamber top 110 and a chamber bottom 115 .
  • the chamber bottom 115 preferably comprises a chamber side wall 120 and a chamber bottom surface 125 .
  • a gel support 130 is formed on the chamber bottom surface.
  • the shipping chamber comprises an insert 135 comprising a permeable membrane 140 and insert extensions 142 .
  • the skin equivalent 145 is formed on the permeable membrane 140 .
  • the permeable membrane 140 of the insert 135 is placed in contact with the gel support 130 .
  • the height of the gel support 130 within the shipping chamber 100 is such that when the insert 135 is placed in the shipping chamber 100 on gel support 130 , the insert extensions 142 extend upward and contact the chamber top 110 when chamber top 110 is placed on chamber bottom 115 so that the insert 135 is secured on the gel support 130 by the downward force exerted by the chamber top 110 and the insert extensions 142 .
  • the temperature of the sterile package is reduced to about 2-8 degrees C.
  • organotypically cultured skin equivalents can be shipped and stored at lowered temperatures and maintain their viability for use in skin grafting and wound closing procedures.
  • the ability to ship and store at lowered temperatures greatly increases the flexibility of manufacturing, shipping and using organotypically cultured skin equivalents. This stands in direct contrast to the manufacturing, shipping, and use of other organotypically cultured skin equivalents such as APLIGRAF® which is usable for less than ten days and must be maintained between 20 and 23° C. until used.
  • organotypically cultured skin equivalents can be preferably used up to 15 days after the packaging date. The additional storage time greatly enhances the flexibility of use of the organotypically cultured skin equivalents.
  • the sterile package is placed in an insulated container and packed with cold packs, preferably gel cold packs, to maintain the temperature of the sterile package at 2-8 degrees C. during shipping.
  • cold packs preferably gel cold packs
  • the sterile package is removed from the insulated container and placed in a refrigeration unit for storage at 2-8 C. until the time of use.
  • the integrity (and sterility) of the sterile package is maintained until immediately prior to use by a physician or other care giver, for example, in an operating room.
  • an intervening culture step or revival period is not required prior to use of the organotypically cultured skin equivalent in a skin grafting or wound closure procedure. This feature represents a substantial, unexpected improvement over prior methods where the tissue either must be stored at a higher temperature or revived at a higher temperature in a liquid media for use.
  • preserved cells, organs, and tissues of the present invention may be used therapeutically.
  • the cells, organs, and tissues are utilized to treat chronic skin wounds.
  • Successful treatment of chronic skin wounds e.g., venous ulcers, diabetic ulcers, pressure ulcers
  • the healing of such a wound often times takes well over a year of treatment.
  • Treatment options currently include dressings and debridement (use of chemicals or surgery to clear away necrotic tissue), and/or antibiotics in the case of infection. These treatment options take extended periods of time and high amounts of patient compliance. As such, a therapy that can increase a practitioner's success in healing chronic wounds and accelerate the rate of wound healing would meet an unmet need in the field.
  • the present invention contemplates treatment of skin wounds with skin equivalents comprising the cells of the present invention (e.g., NIKS® cells).
  • NIKS® cells are topically applied to wound sites.
  • skin equivalents comprising NIKS® cells are used for engraftment on partial thickness wounds.
  • skin equivalents comprising NIKS® cells are used for engraftment on full thickness wounds.
  • skin equivalents comprising NIKS® cells are used to treat numerous types of internal wounds, including, but not limited to, internal wounds of the mucous membranes that line the gastrointestinal tract, ulcerative colitis, and inflammation of mucous membranes that may be caused by cancer therapies.
  • skin equivalents comprising NIKS® cells expressing are used as a temporary or permanent wound dressing.
  • Skin equivalents comprising cells also find use in wound closure and burn treatment applications.
  • the use of autografts and allografts for the treatment of burns and wound closure is described in Myers et al., A. J. Surg. 170(1):75-83 (1995) and U.S. Pat. Nos. 5,693,332; 5,658,331; and 6,039,760, each of which is incorporated herein by reference.
  • the skin equivalents may be used in conjunction with dermal replacements such as DERMAGRAFT or INTEGRA.
  • the skin equivalents are produced using both a standard source of keratinocytes (e.g., NIKS® cells) and keratinocytes from the patient that will receive the graft. Therefore, the skin equivalent contains keratinocytes from two different sources. In still further embodiments, the skin equivalent contains keratinocytes from a human tissue isolate. Accordingly, the present invention provides methods for wound closure, including wounds caused by burns, comprising providing a skin equivalent and a patient suffering from a wound and treating the patient with the skin equivalent under conditions such that the wound is closed.
  • the cells are engineered to provide additional therapeutic agents to a subject.
  • the present invention is not limited to the delivery of any particular therapeutic agent. Indeed, it is contemplated that a variety of therapeutic agents may be delivered to the subject, including, but not limited to, enzymes, peptides, peptide hormones, other proteins, ribosomal RNA, ribozymes, and antisense RNA. These therapeutic agents may be delivered for a variety of purposes, including but not limited to the purpose of correcting genetic defects. In some particular preferred embodiments, the therapeutic agent is delivered for the purpose of detoxifying a patient with an inherited inborn error of metabolism (e.g., aminoacidopathesis) in which the graft serves as wild-type tissue.
  • an inherited inborn error of metabolism e.g., aminoacidopathesis
  • the cells are transformed with a DNA construct encoding a therapeutic agent (e.g., insulin, clotting factor IX, erythropoietin, etc) and the cells grafted onto the subject.
  • a therapeutic agent e.g., insulin, clotting factor IX, erythropoietin, etc
  • the therapeutic agent is then delivered to the patient's bloodstream or other tissues from the graft.
  • the nucleic acid encoding the therapeutic agent is operably linked to a suitable promoter.
  • the present invention is not limited to the use of any particular promoter. Indeed, the use of a variety of promoters is contemplated, including, but not limited to, inducible, constitutive, tissue specific, and keratinocyte specific promoters.
  • the nucleic acid encoding the therapeutic agent is introduced directly into the keratinocytes (i.e., by calcium phosphate co-precipitation or via liposome transfection).
  • the nucleic acid encoding the therapeutic agent is provided as a vector and the vector is introduced into the keratinocytes by methods known in the art.
  • the vector is an episomal vector such as a plasmid.
  • the vector integrates into the genome of the keratinocytes. Examples of integrating vectors include, but are not limited to, retroviral vectors, adeno-associated virus vectors, and transposon vectors.
  • This example describes a method for the production of skin equivalents.
  • TM 3T3 feeder cell medium
  • FGM human fibroblast growth medium
  • NM NIKS® medium
  • PM plating medium
  • SMA stratification medium A
  • SMB stratification medium B
  • FGM is a commercially available fibroblast growth medium (Clonetics) that is used to propagate the normal human dermal fibroblast cells (NHDFs) for use in STRATAGRAFT® skin equivalent and STATATEST skin equivalent dermal equivalent layers.
  • NHDFs normal human dermal fibroblast cells
  • NM is used to grow NIKS® keratinocytes.
  • NM is a 3:1 mixture of Ham's F-12 medium (GibcoBRL) and DME supplemented with 2.5% fetal clone II (Hyclone), 0.4 ⁇ g/ml hydrocortisone (Calbiochem), 8.4 ng/ml cholera toxin (ICN), 5 ⁇ g/ml insulin (Sigma), 24 ⁇ g/ml adenine (Sigma) and 10 ng/ml epidermal growth factor (EGF, R&D systems).
  • PM is the medium used when NIKS® cells are seeded onto a dermal equivalent.
  • PM is the same NM with the exception that EGF is removed, the serum is reduced to 0.2%, and CaCl 2 (Sigma) is supplemented to a final calcium concentration of 1.88 nm.
  • SMA is the same as PM with the addition of 1 mg/ml bovine serum albumin (BSA), 1 ⁇ M isoproterenol, 10 ⁇ M carnitine, 10 ⁇ M serine, 25 ⁇ M oleic acid, 15 ⁇ M linoleic acid, 7 ⁇ M arachidonic acid, 1 ⁇ M ⁇ -tocopherol, 0.05 mg/ml ascorbic acid (all from Sigma), and 1 ng/ml EGF.
  • SMB is used during the epidermal stratification phase of STRATATEST skin equivalent and STRATAGRAFT® skin equivalent growth. SMB is the same as SMA but without the presence of the fetal clone II serum supplement.
  • 3T3 feeder cells Prior to starting STRATAGRAFT® skin equivalent organotypic cultures, 3T3 feeder cells are prepared and then used either fresh or frozen for later use. 3T3 cells are grown to confluence and treated with mitomycin-C (4 ug/ml in TM, Roche) for four hours. The cells are then washed, resuspended, and plated at a density of 1.25 ⁇ 10 6 per 100 mm tissue culture dish to support NIKS® growth. If frozen feeders are used, a single frozen ampoule containing 1 ml with 2 ⁇ 10 6 is thawed, diluted with fresh TM and plated onto two 100 mm tissue culture dishes. This is done for as many dishes as will be needed for NIKS® cell growth one prior to plating the NIKS® cells.
  • Dermal equivalent preparation On day 0, frozen NHDF cells are thawed and plated. The cells are fed FGM-2 the next day (day 1) to residual cryoprotectant and again on day 3. On day 4, they are harvested for in the dermal equivalent.
  • rat-tail collagen Type I, Becton-Dickinson
  • a mixture of concentrated Ham's F12 medium (8.7 ⁇ normal strength and buffered with HEPES at pH 7.5) is mixed with fetal clone II (supplemented bovine serum). These two solutions are 11.5 and 10% of the final solution volume. 1N NaOH is added to the medium mixture (2.5% of final solution).
  • the diluted collagen is then added (74%) to the mixture.
  • a 2% volume of suspended fibroblasts (1.3 ⁇ 10 6 for STRATAGRAFT® skin equivalent) is added to the mixture.
  • 100 ⁇ l is aliquoted into tissue culture inserts (MILLICELL from Millipore Corp.) and placed in a 100 mm tissue culture dish. After 30 minutes for gel formation, the dish is flooded with 20 ml of FGM-2. One or two drops of the F-12-serum mix are placed on the surface of each dermal equivalent.
  • STRATAGRAFT® skin equivalent uses TRANSWELL inserts from Corning. A 13 ml dermal equivalent is poured into each insert.
  • FGM-2 FGM-2 is placed around the TRANSWELL insert in a 150 mm tissue culture dish and 10 ml is placed on top of the dermal equivalent.
  • the inserts are placed in 37° C., 5% CO 2 , 90% relative humidity incubator until used.
  • the dermal equivalents are seeded with NIKS® cells, they are lifted to the air interface by placing them onto a sterile stainless steel mesh to supply medium through the bottom of the tissue culture insert.
  • NIKS® Growth and Seeding On day 0, the feeders are plated in NM. On day 1, NIKS® cells are plated onto the feeders at a density of approximately 3 ⁇ 10 5 cells per 100 mm dish. On day 2, the NIKS® cells are fed fresh NM to remove residual cryoprotectant. The NIKS® cells are fed again on days 4 and 6. (For STRATAGRAFT® skin equivalent size cultures, the NIKS® cultures are started a week earlier due to the increase in number of cells needed). On day 8, the NIKS® cells are harvested, counted, and resuspended in PM. 4.65 ⁇ 10 5 NIKS® cells/cm 2 are seeded onto the surface of the MIILLICELL or TRANSWELL inserts.
  • the dishes are fed 30 ml PM (100 ml for STRATAGRAFT® skin equivalent) underneath the metal lifter and placed back into the incubator.
  • PM 100 ml for STRATAGRAFT® skin equivalent
  • the cultures are fed SMA.
  • days 12, 14, 16, 18, 20, and 22 the cultures are fed SMB.
  • the cultures are transferred to a 75% humidity incubator where they remain for the rest of their growth.
  • STRATAGRAFT® skin tissue is a living skin substitute tissue that has a fully-stratified layer of viable epidermal keratinocytes on a collagen gel containing normal human dermal fibroblasts.
  • the uppermost epidermal layers form a permeability barrier that prevents excessive moisture loss through the epidermis.
  • Assays that measure these key structural and functional properties have been identified as stability-indicating assays for monitoring the quality of STRATAGRAFT® skin tissue over time.
  • STRATAGRAFT® skin tissue lasts 31 days.
  • STRATAGRAFT® skin tissues are removed from organotypic culturing conditions and placed onto HEPES-buffered nutrient-agarose shipping chambers, which are designed to maintain the viability, barrier function, and histological architecture of STRATAGRAFT® skin tissues prior to clinical use.
  • This study was conducted to compare STRATAGRAFT® skin tissue properties following storage on shipping chambers for 1 day at 2°-8° C. or 20°-25° C.
  • Two independent lots of STRATAGRAFT® skin tissue were analyzed for viability, barrier function, and histology after a 1 day storage period at 2°-8° C. or 20°-25° C.
  • Barrier function data are presented below in Tables 3 and 4.
  • the acceptance criteria for barrier function are all readings must have an initial DPM value ⁇ 294 and a DPM change over a 10 second interval ⁇ 658.
  • All other readings from STRATAGRAFT® skin tissues stored at 2°-8° C. passed the acceptance criteria and were comparable to barrier function readings from tissues stored at 20°-25° C.
  • the barrier function improved slightly following storage at either temperature compared to the Day 28 QC tissues. This data demonstrated that the barrier function of STRATAGRAFT® skin tissues stored for 1 day at 20°-25° C. or 2°-8° C. is comparable.
  • the typical appearance of a paraffin embedded STRATAGRAFT® tissue section stained with hematoxylin and eosin includes fibroblasts in the dermal layer, a basal layer of small, nucleated keratinocytes at the junction between the epidermal and dermal layers, multiple layers of differentiating keratinocytes above the basal layer, and a layer of flattened corneocytes. All tissues conformed to the specifications for histology.
  • the STRATAGRAFT® skin tissues stored at 2°-8° C. had tissue architecture comparable to tissues stored at 20°-25° C. and both sets of stored tissues were comparable to the Day 28 QC tissues.
  • This example demonstrates that skin equivalents stored for 8 days at 2-8 C are comparable to, or superior to, tissues stored for only 1 day at 20-25 C. Reduction of the storage temperature has been shown to maintain tissue quality comparable to tissues stored at 20°-25° C. (See Example 2). The ability to store STRATAGRAFT® tissue for eight days at 2-8° C. would increase the number of days STRATAGRAFT® tissue is available for clinical use. This study tested the comparability of tissues stored for one day at 20-25° C. with tissues stored at 2-8° C. for eight days. Tissue viability was improved in the tissues that were stored at 2-8° C., even though these tissues were stored for seven additional days.
  • This study used one batch of tissues manufactured under cGMP at the WCBF and two batches produced at the Stratatech pilot production facility.
  • One tissue from each batch was analyzed on process day 28.
  • the remaining six tissues were fed on day 28 and 30, and placed onto shipping chambers on process day 31.
  • Three tissues from each batch were stored at 20-25° C. for 1 day prior to analysis.
  • the remaining three tissues from each batch were stored at 2-8° C. for 8 days. Prior to analysis, the tissues stored for 8 days at 2-8° C. were equilibrated at 20-25° C. for one hour.
  • Viability data is presented in Table 5 and FIG. 3 . All viability samples met the acceptance criteria (A 550 ⁇ 0.533). However, in all three intra-lot comparisons ( FIG. 3 left panel), the viability of tissues stored at 2-8° C. for 8 days was higher than tissues stored for one day at 20-25° C. The mean A 550 value for the tissues stored at 20-25° C. for 1 day was 0.709, compared to 0.831 for tissues stored at 2-8° C. for eight days. This data indicates that storage of STRATAGRAFT® tissues at 2-8° C. is better able to maintain tissue viability than storage at 20-25° C.
  • Tissues were analyzed with a Nova impedance meter. Data are presented in Tables 6 and 7. All readings met the lot-release criteria for STRATAGRAFT® tissue (Initial reading ⁇ 294, Change ⁇ 658). This data suggests that storage of STRATAGRAFT® tissue for eight days at 2-8° C. does not adversely affect tissue barrier function, compared to tissues analyzed after storage at 20-25° C. for 1 day.
  • STRATAGRAFT® tissue stored for eight days at 2-8° C. had viability, histology and barrier function properties comparable to or better than tissues stored for 1 day at 20-25° C. This result demonstrates that up to eight days of storage at 2-8° C. does not adversely affect STRATAGRAFT® tissue properties.
  • STRATAGRAFT® tissues produced at Stratatech's process development laboratory were packaged onto nutrient-agarose shipping chambers on Day 28 of the production process and stored at approximately 2-8° C., 15° C., or 22.5° C. for 1, 4, 8, 15, or 29 days. Tissues were analyzed for viability and histology after the indicated storage periods. Barrier function measurements were not performed on all tissues, and so this data is not presented.
  • the viability data from this study is shown in FIG. 4 . All storage temperatures were equivalent in their ability to maintain tissue viability for up to 4 days of storage. After 8 days of storage, viability results from tissues stored at 2-8° C. or 15° C. were comparable to each other and were superior to those of tissues stored at 20-25° C. After 15 or 29 days of storage, tissues stored at 2-8° C. exhibited higher viability compared to tissues stored at 15° C. or 20-25° C.
  • Tissues from three independent STRATAGRAFT® skin tissue lots produced at the WCBF were used for this study.
  • One randomly chosen tissue from each lot was tested on Day 28 of the STRATAGRAFT® skin tissue production process.
  • the six remaining tissues in each lot were fed SMB medium on process Day 28 and process Day 30.
  • On process Day 31, the 6 tissues were placed onto shipping chambers and stored at 2-8° C. for either 1, 8, or 15 days. After the specified storage interval, the tissues were incubated at 20-25° C. for 1 hour and then analyzed for viability, barrier function, and histology.
  • Viability data is presented in Tables 8 and 9 and in FIG. 4 .
  • the acceptance criterion is that all samples have an A 550 ⁇ 0.533.
  • Barrier function data is presented below in Tables 10 and 11 and in FIG. 5 .
  • the acceptance criteria for barrier function are all readings must have an initial DPM value ⁇ 294 and a DPM change over a 10 second interval ⁇ 658.
  • tissues stored at 2-8° C. for 15 days exhibited typical histological architecture, consisting of a dermis containing fibroblasts and an epidermis containing all required tissue layers.
  • This example describes how the shipping chambers and sterile packages for shipping are made.
  • a solution of 3% agarose is prepared by mixing 45 g agarose in 1455 ml water. The mixture is stirred and then autoclaved (121 C for 60 min.) to dissolve the agarose.
  • 2 ⁇ media solution is prepared by mixing in 1455 ml water: 24 g F12 media powder, 10.0 g DMEM media powder and 7.2 g HEPES powder. The mixture is stirred until all powder is dissolved and the pH is adjusted to 7.3 to 7.5.
  • the 2 ⁇ media solution and 3% agarose solution are placed in 40 C water baths for 30-60 minutes. The 2 ⁇ media solution is then sterile-filtered and aseptically added to the 3% agarose solution though a SterivexTM filter.
  • 60 ml of the resulting solution is then aseptically dispensed into a sterile p150 culture dish (150 mm ⁇ 20 mm circular tissue culture dish) and allowed to gel.
  • shipping chambers are packed into a heat sealable sterile bag for storage until use.
  • a skin equivalent in a Transwell insert (7.5 cm diameter (44 cm 2 ), pore size 0.4 micron) is aseptically placed on the agarose in the shipping chamber and the p150 plate top is placed on the shipping chamber and secured under aseptic conditions.
  • the shipping chamber is then placed in a sterile heat sealable pouch and sealed to provide a shipping package.
  • the shipping package is stored and shipped at 2-8 C, and is storable at the site of use at 2-8 C for 8-15 days from the time of packaging until immediately prior to the time of use.
  • the integrity of the package may be maintained until the time of use and revival of the skin equivalent prior to use is not necessary.
  • This example describes a simplified method for the production of skin equivalents.
  • Media The organotypic culture process uses three different culture media, all based on the formulation of SMB medium described in U.S. Pat. No. 7,407,805, with the exception that cholera toxin is omitted from all media.
  • FM01 is used to propagate the normal human dermal fibroblasts (NHDFs) for use in skin equivalent dermal equivalent layers.
  • NHDFs normal human dermal fibroblasts
  • FM01 has the same formulation as SMB except that it contains Fetal Clone II serum (2% final) and lacks cholera toxin.
  • KM01 is used to grow NIKS® keratinocytes and has the same composition as SMB except that it contains 2.5% fetal clone II, and additional epidermal growth factor (EGF) is added to a final concentration of 5 ng/ml.
  • SM01 is used during the epidermal stratification phase of skin equivalent production and is identical to SMB except for the omission of cholera toxin.
  • Dermal equivalent preparation On day 0, frozen NHDF cells are thawed and plated. The cells are fed FM01 the next day (day 1) to remove residual cryoprotectant and again on day 3. On day 4, they are harvested for use in the dermal equivalent.
  • Type I rat-tail collagen is first diluted to 3 mg/ml in 0.03N acetic acid and chilled on ice. A mixture of concentrated Ham's F12 medium (8.7 ⁇ normal strength and buffered with HEPES at pH 7.5) is mixed with fetal clone II. These two solutions are 11.3 and 9.6% of the final solution volume. 1N NaOH is added to the medium mixture (2.4% of final solution). The diluted collagen is then added (74.7%) to the mixture.
  • a 2% volume of suspended fibroblasts (2.78 ⁇ 10 6 /ml) is added to the mixture.
  • 9 ml of the final dermal equivalent mixture is poured into each 75 mm TRANSWELL insert (Corning Costar). After a 50-70 minute gel formation period, the Transwell inserts are transferred to the surface of a stainless steel mesh in a 150 mm culture dish.
  • 80 ml of FM01 is placed in the 150 mm dish outside the TRANSWELL insert and 10 ml is placed on top of the dermal equivalent.
  • the dermal equivalents are placed in 37° C., 5% CO 2 , 90% relative humidity incubator for 4-5 days prior to use in the organotypic cultures.
  • NIKS® Growth and Seeding NIKS® cells are thawed and plated at a density of approximately 5 ⁇ 10 5 cells per 100 mm dish. NIKS® culture can be performed in the presence or absence of murine feeder cells. On day 1, the NIKS® cells are fed fresh KM01 to remove residual cryoprotectant. The NIKS® cells are fed again on day 3. On day 4, the NIKS® cells are harvested from the initial p100 cultures and seeded into 225 cm 2 culture flasks at a density of 1.2 ⁇ 10 6 per flask. The NIKS® cultures are fed fresh medium on Days 7 and 8. On day 9, the NIKS® cells are harvested, counted, and resuspended in SM01.
  • NIKS® cells/cm 2 are seeded onto the surface of the dermal equivalents.
  • the dishes are cultures are fed and lifted to the air-medium interface. Cultures are transferred to a controlled humidity incubator set to 75% where they remain for the rest of their growth. Cultures are fed SM01 on days 14, 18, 22, 25, 28, and 30.
  • STRATAGRAFT® skin tissues produced using simplified procedures on shipping chambers for up to 15 days is highly desirable as it would enhance the availability of the tissue for clinical use.
  • This example demonstrates that storage of skin equivalents produced using simplified procedures on nutrient-agarose shipping chambers for up to 15 days at 2-8° C. is acceptable.
  • STRATAGRAFT® tissues produced at Stratatech's process development laboratory were packaged onto nutrient-agarose shipping chambers on Day 31 of the production process and stored at approximately 2-8° C. for 8 or 15 days. Tissues were analyzed for viability, barrier function, and histology after the indicated storage periods.
  • STRATAGRAFT® skin tissues stored at 2-8° C. for 8 or 15 days exhibited all of the typical epidermal layers atop the collagen dermis containing fibroblasts.
  • Several common storage-related effects were seen in these tissues including an increase in the number of condensed nuclei and a reduction in the eosin staining in the upper epidermal layers.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Hematology (AREA)
  • Mechanical Engineering (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
US12/271,455 2007-11-14 2008-11-14 Cold storage of organotypically cultured skin equivalents for clinical applications Abandoned US20090145087A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/271,455 US20090145087A1 (en) 2007-11-14 2008-11-14 Cold storage of organotypically cultured skin equivalents for clinical applications
US15/375,755 US10743533B2 (en) 2007-11-14 2016-12-12 Cold storage of organotypically cultured skin equivalents for clinical applications

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98791107P 2007-11-14 2007-11-14
US12/271,455 US20090145087A1 (en) 2007-11-14 2008-11-14 Cold storage of organotypically cultured skin equivalents for clinical applications

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/375,755 Continuation US10743533B2 (en) 2007-11-14 2016-12-12 Cold storage of organotypically cultured skin equivalents for clinical applications

Publications (1)

Publication Number Publication Date
US20090145087A1 true US20090145087A1 (en) 2009-06-11

Family

ID=40639155

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/271,455 Abandoned US20090145087A1 (en) 2007-11-14 2008-11-14 Cold storage of organotypically cultured skin equivalents for clinical applications
US15/375,755 Active US10743533B2 (en) 2007-11-14 2016-12-12 Cold storage of organotypically cultured skin equivalents for clinical applications

Family Applications After (1)

Application Number Title Priority Date Filing Date
US15/375,755 Active US10743533B2 (en) 2007-11-14 2016-12-12 Cold storage of organotypically cultured skin equivalents for clinical applications

Country Status (10)

Country Link
US (2) US20090145087A1 (da)
EP (1) EP2215212B1 (da)
JP (1) JP5719172B2 (da)
AU (1) AU2008322567B2 (da)
CA (1) CA2705758C (da)
DK (1) DK2215212T3 (da)
ES (1) ES2649534T3 (da)
NO (1) NO2215212T3 (da)
PT (1) PT2215212T (da)
WO (1) WO2009065005A1 (da)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100119615A1 (en) * 2008-11-04 2010-05-13 Stratatech Corporation Dried and irradiated skin equivalents for ready use
US20100330046A1 (en) * 2009-05-21 2010-12-30 Stratatech Corporation Human skin substitutes expressing il-12
US20150132737A1 (en) * 2012-05-03 2015-05-14 Genoskin System for keeping alive and transporting skin biopsies and applications of said system
US20160040117A1 (en) * 2014-08-08 2016-02-11 James David Pfau Methods and an Apparatus for Transporting Live Cells
WO2018140755A1 (en) * 2017-01-27 2018-08-02 Stratatech Corporation Tissue container systems
US10091983B2 (en) 2013-03-13 2018-10-09 Stratatech Corporation Cryopreservation of viable human skin substitutes
US10743533B2 (en) 2007-11-14 2020-08-18 Stratatech Corporation Cold storage of organotypically cultured skin equivalents for clinical applications

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024519731A (ja) * 2021-05-28 2024-05-21 ストラタテック コーポレーション 同種異系培養ケラチノサイト製品

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4958506A (en) * 1988-03-07 1990-09-25 Guilhem Jacques R J Container for transporting grafts
US5110722A (en) * 1989-11-09 1992-05-05 Cryolife, Inc. Cell, tissue or organ storage solution
US5405742A (en) * 1993-07-16 1995-04-11 Cyromedical Sciences, Inc. Solutions for tissue preservation and bloodless surgery and methods using same
US5681740A (en) * 1995-06-05 1997-10-28 Cytotherapeutics, Inc. Apparatus and method for storage and transporation of bioartificial organs
WO1999035453A1 (fr) * 1998-01-12 1999-07-15 Safetherm S.A. Procede de traitement de donnees relatives au transport de materiel biologique et dispositif pour sa mise en oeuvre
US5968546A (en) * 1997-05-16 1999-10-19 Baur; Marcus Keratinocyte culture from precursor cells
US20020164793A1 (en) * 2001-03-02 2002-11-07 Conrad Paul Barth Skin substitutes and uses thereof
US20040043481A1 (en) * 2002-06-13 2004-03-04 Wilson Wolf Manufacturing Corporation Apparatus and method for culturing and preserving tissue constructs
WO2007033051A2 (en) * 2005-09-12 2007-03-22 Genzyme Corporation Thermally insulated transport container for cell-based products and related methods

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4485096A (en) 1982-02-26 1984-11-27 Massachusetts Institute Of Technology Tissue-equivalent and method for preparation thereof
IL95429A (en) 1989-09-15 1997-09-30 Organogenesis Living tissue equivalents comprising hydrated collagen lattice and a collagen gel and their production
ES2111566T3 (es) 1990-04-24 1998-03-16 Mark Eisenberg Equivalentes compuestos de piel viva.
IT1248934B (it) 1990-06-01 1995-02-11 Fidia Spa Membrane forate biocompatibili,processi per la loro preparazione,loro impiego come supporto per la crescita in vitro di cellule epiteliali, pelli artificiali cosi' ottenute e loro impiego nei trapianti di pelle
WO1993008776A1 (en) 1991-11-01 1993-05-13 Culture Technology, Inc. Cultured skin graft carrier
US5843766A (en) * 1995-06-07 1998-12-01 Advanced Tissue Sciences, Inc. Apparatus for the growth and packaging of three dimensional tissue cultures
US5693332C1 (en) 1995-08-11 2001-01-09 Univ California Human keratinocytes supported on a hydrophilic membrane and methods of using same to effect wound closure
US5989837A (en) 1998-07-13 1999-11-23 Wisconsin Alumni Research Foundation Immortalized human keratinocyte cell line
US6146883A (en) * 1998-09-14 2000-11-14 Navicyte, Inc. Packing device for transporting confluent cell monolayers
US7014849B1 (en) 1999-07-20 2006-03-21 Dfb Pharmaceuticals, Inc. Keratinocyte culture and uses thereof
FR2798668B1 (fr) * 1999-09-17 2001-12-21 Genevrier Lab Nouveau procede pour le transport des cellules et les greffes ainsi realisees
US6974697B2 (en) 2001-03-02 2005-12-13 Stratech Corporation Skin substitutes with improved barrier function
JP2003070460A (ja) * 2001-09-06 2003-03-11 Menicon Co Ltd 膜組織用裏打ち基材及びそれを用いた膜組織の保存／輸送方法
IL164817A0 (en) 2002-04-30 2005-12-18 Stratatech Corp Keratinocytes expressing exogenous angiogenic growth factors
AU2003254298A1 (en) 2002-08-02 2004-02-23 Stratatech Corporation Species specific dna detection
JP2006526413A (ja) 2003-05-30 2006-11-24 ストラタテック コーポレーション 臓器の室温保存法
EP3100611B1 (en) 2003-08-01 2018-09-12 Stratatech Corporation Human skin equivalents expressing exogenous polypeptides
US20060141627A1 (en) 2004-11-18 2006-06-29 Stratatech Corporation Vectors for stable gene expression
EP1858333B1 (en) * 2005-03-01 2015-12-23 Stratatech Corporation Human skin equivalents expressing exogenous polypeptides
WO2006101834A1 (en) 2005-03-17 2006-09-28 Stratatech Corporation Skin substitutes with improved purity
DK2215212T3 (da) 2007-11-14 2017-11-27 Stratatech Corp Kold opbevaring af organotypisk dyrkede hudækvivalenter til kliniske anvendelser
KR101020486B1 (ko) 2008-09-23 2011-03-08 강원대학교산학협력단 신규한 1,3-부타다이엔-2-일 메틸 아민 유도체 및 유기 인듐 시약을 이용한 이의 제조방법
AU2009313656B2 (en) 2008-11-04 2014-02-20 Stratatech Corporation Dried and irradiated skin equivalents for ready use
WO2010135655A2 (en) 2009-05-21 2010-11-25 Stratatech Corporation Human skin substitutes expressing il-12

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4958506A (en) * 1988-03-07 1990-09-25 Guilhem Jacques R J Container for transporting grafts
US5110722A (en) * 1989-11-09 1992-05-05 Cryolife, Inc. Cell, tissue or organ storage solution
US5405742A (en) * 1993-07-16 1995-04-11 Cyromedical Sciences, Inc. Solutions for tissue preservation and bloodless surgery and methods using same
US5681740A (en) * 1995-06-05 1997-10-28 Cytotherapeutics, Inc. Apparatus and method for storage and transporation of bioartificial organs
US5968546A (en) * 1997-05-16 1999-10-19 Baur; Marcus Keratinocyte culture from precursor cells
WO1999035453A1 (fr) * 1998-01-12 1999-07-15 Safetherm S.A. Procede de traitement de donnees relatives au transport de materiel biologique et dispositif pour sa mise en oeuvre
US20020164793A1 (en) * 2001-03-02 2002-11-07 Conrad Paul Barth Skin substitutes and uses thereof
US20040043481A1 (en) * 2002-06-13 2004-03-04 Wilson Wolf Manufacturing Corporation Apparatus and method for culturing and preserving tissue constructs
US7229820B2 (en) * 2002-06-13 2007-06-12 Wilson Wolf Manufacturing Corporation Apparatus and method for culturing and preserving tissue constructs
WO2007033051A2 (en) * 2005-09-12 2007-03-22 Genzyme Corporation Thermally insulated transport container for cell-based products and related methods

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DeBono et al. "The Survival of Human Skin Stored by Refrigeration at 4C in McCoy's 5A Medium: Does Oxygenation of the Medium Improve Storage Time?". Plastic and Reconstructive Surgery Vol. 102, No. 1, 1998: 78-83. *
McGregor et al. Fundamental Techniques of Plastic Surgery and Their Surgical Applications, Tenth Edition, pp. 35-50 and 121-123. 2000. *
Pousa Real F. "Skin Bank Organization." Annals of the MBC - vol. 3 - n 1 - March 1990. Downloaded from on 05/05/2015. *

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10743533B2 (en) 2007-11-14 2020-08-18 Stratatech Corporation Cold storage of organotypically cultured skin equivalents for clinical applications
US9867904B2 (en) 2008-11-04 2018-01-16 Stratatech Corporation Dried and irradiated skin equivalents for ready use
US8580314B2 (en) 2008-11-04 2013-11-12 Stratatech Corporation Dried and irradiated skin equivalents for ready use
US8685463B2 (en) 2008-11-04 2014-04-01 Stratatech Corporation Dried and irradiated skin equivalents for ready use
US8992997B2 (en) 2008-11-04 2015-03-31 Stratatech Corporation Dried and irradiated skin equivalents for ready use
US9526811B2 (en) 2008-11-04 2016-12-27 Stratatech Corporation Dried and irradiated skin equivalents for ready use
US20100119615A1 (en) * 2008-11-04 2010-05-13 Stratatech Corporation Dried and irradiated skin equivalents for ready use
US20100330046A1 (en) * 2009-05-21 2010-12-30 Stratatech Corporation Human skin substitutes expressing il-12
US11911444B2 (en) 2009-05-21 2024-02-27 Stratatech Corporation Use of human skin substitutes expressing exogenous IL-12 to treat a wound bed
US9585381B2 (en) * 2012-05-03 2017-03-07 Genoskin System for keeping alive and transporting skin biopsies and applications of said system
US20150132737A1 (en) * 2012-05-03 2015-05-14 Genoskin System for keeping alive and transporting skin biopsies and applications of said system
US10091983B2 (en) 2013-03-13 2018-10-09 Stratatech Corporation Cryopreservation of viable human skin substitutes
US11297829B2 (en) 2013-03-13 2022-04-12 Stratatech Corporation Cryopreservation of viable human skin substitutes
US9868931B2 (en) * 2014-08-08 2018-01-16 James David Pfau Methods and an apparatus for transporting live cells
US20160040117A1 (en) * 2014-08-08 2016-02-11 James David Pfau Methods and an Apparatus for Transporting Live Cells
WO2018140755A1 (en) * 2017-01-27 2018-08-02 Stratatech Corporation Tissue container systems
CN110461149A (zh) * 2017-01-27 2019-11-15 斯特拉塔泰克公司 组织容器系统
US11406102B2 (en) 2017-01-27 2022-08-09 Stratatech Corporation Tissue container systems

Also Published As

Publication number Publication date
EP2215212A1 (en) 2010-08-11
JP5719172B2 (ja) 2015-05-13
WO2009065005A1 (en) 2009-05-22
DK2215212T3 (da) 2017-11-27
EP2215212A4 (en) 2013-02-27
CA2705758C (en) 2015-10-06
CA2705758A1 (en) 2009-05-22
EP2215212B1 (en) 2017-08-30
AU2008322567A1 (en) 2009-05-22
NO2215212T3 (da) 2018-01-27
US10743533B2 (en) 2020-08-18
ES2649534T3 (es) 2018-01-12
JP2011502538A (ja) 2011-01-27
US20170339943A1 (en) 2017-11-30
PT2215212T (pt) 2017-12-01
AU2008322567B2 (en) 2013-01-17

Similar Documents

Publication Publication Date Title
US10743533B2 (en) Cold storage of organotypically cultured skin equivalents for clinical applications
AU2021261937B2 (en) Cryopreservation of viable human skin substitutes
US9867904B2 (en) Dried and irradiated skin equivalents for ready use
AU2018211945B2 (en) Tissue container systems

Legal Events

Date Code Title Description
AS Assignment

Owner name: STRATATECH CORPORATION, WISCONSIN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ALLEN-HOFFMANN, B. LYNN;PIRNSTILL, JOHN C.;REEL/FRAME:022132/0286

Effective date: 20090119

AS Assignment

Owner name: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AG

Free format text: NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS;ASSIGNOR:STRATATECH CORPORATION;REEL/FRAME:040059/0222

Effective date: 20160916

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: INO THERAPEUTICS LLC, MISSOURI

Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 040059, FRAME 0222;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0083

Effective date: 20231114

Owner name: IKARIA THERAPEUTICS LLC, NEW JERSEY

Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 040059, FRAME 0222;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0083

Effective date: 20231114

Owner name: THERAKOS, INC., MISSOURI

Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 040059, FRAME 0222;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0083

Effective date: 20231114

Owner name: ST SHARED SERVICES LLC, MISSOURI

Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 040059, FRAME 0222;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0083

Effective date: 20231114

Owner name: INFACARE PHARMACEUTICAL CORPORATION, MISSOURI

Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 040059, FRAME 0222;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0083

Effective date: 20231114

Owner name: MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.), IRELAND

Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 040059, FRAME 0222;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0083

Effective date: 20231114

Owner name: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED, IRELAND

Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 040059, FRAME 0222;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0083

Effective date: 20231114

Owner name: VTESSE LLC (F/K/A VTESSE INC.), MISSOURI

Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 040059, FRAME 0222;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0083

Effective date: 20231114

Owner name: SUCAMPO PHARMA AMERICAS LLC, MISSOURI

Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 040059, FRAME 0222;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0083

Effective date: 20231114

Owner name: STRATATECH CORPORATION, WISCONSIN

Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 040059, FRAME 0222;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0083

Effective date: 20231114

Owner name: SPECGX LLC, MISSOURI

Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 040059, FRAME 0222;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0083

Effective date: 20231114

Owner name: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.), MISSOURI

Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 040059, FRAME 0222;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0083

Effective date: 20231114

Owner name: MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED), IRELAND

Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 040059, FRAME 0222;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0083

Effective date: 20231114

Owner name: MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED), IRELAND

Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 040059, FRAME 0222;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0083

Effective date: 20231114

Owner name: MEH, INC., MISSOURI

Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 040059, FRAME 0222;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0083

Effective date: 20231114

Owner name: IMC EXPLORATION COMPANY, MISSOURI

Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 040059, FRAME 0222;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0083

Effective date: 20231114

Owner name: MALLINCKRODT US HOLDINGS LLC, MISSOURI

Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 040059, FRAME 0222;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0083

Effective date: 20231114

Owner name: MALLINCKRODT VETERINARY, INC., MISSOURI

Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 040059, FRAME 0222;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0083

Effective date: 20231114

Owner name: MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.), MISSOURI

Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 040059, FRAME 0222;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0083

Effective date: 20231114

Owner name: LIEBEL-FLARSHEIM COMPANY LLC, MISSOURI

Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 040059, FRAME 0222;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0083

Effective date: 20231114

Owner name: LAFAYETTE PHARMACEUTICALS LLC, MISSOURI

Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 040059, FRAME 0222;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0083

Effective date: 20231114

Owner name: MALLINCKRODT LLC, MISSOURI

Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 040059, FRAME 0222;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0083

Effective date: 20231114

Owner name: MALLINCKRODT ENTERPRISES LLC, MISSOURI

Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 040059, FRAME 0222;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0083

Effective date: 20231114

Owner name: MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.), MISSOURI

Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 040059, FRAME 0222;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0083

Effective date: 20231114

Owner name: CNS THERAPEUTICS, INC., MISSOURI

Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 040059, FRAME 0222;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0083

Effective date: 20231114

Owner name: LUDLOW LLC (F/K/A LUDLOW CORPORATION), MISSOURI

Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 040059, FRAME 0222;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0083

Effective date: 20231114

Owner name: MNK 2011 LLC (F/K/A MALLINCKRODT INC.), MISSOURI

Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 040059, FRAME 0222;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0083

Effective date: 20231114

Owner name: MALLINCKRODT US POOL LLC, MISSOURI

Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 040059, FRAME 0222;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0083

Effective date: 20231114

Owner name: MALLINCKRODT CARRIBEAN, INC., MISSOURI

Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 040059, FRAME 0222;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0083

Effective date: 20231114

Owner name: MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.), MISSOURI

Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 040059, FRAME 0222;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0083

Effective date: 20231114

Owner name: MALLINCKRODT FINANCE GMBH, SWITZERLAND

Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 040059, FRAME 0222;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0083

Effective date: 20231114

Owner name: MALLINCKRODT CB LLC, MISSOURI

Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 040059, FRAME 0222;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0083

Effective date: 20231114

Owner name: MALLINCKRODT INTERNATIONAL FINANCE S.A., LUXEMBOURG

Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 040059, FRAME 0222;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0083

Effective date: 20231114